CVBT Cited as ‘One of the Top Therapies and Technologies Vying to Deliver the Next Decade’s Break-Throughs and Blockbusters’
CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT) today announced that Pharmaceutical Executive magazine has named CVBT’s angiogenesis therapy as “one of the seven top therapies and technologies vying to deliver the next decade’s breakthroughs and blockbusters,” in its August 2007 issue. Pharmaceutical Executive is an award-winning, highly respected global business and marketing magazine for pharmaceutical executives. Angiogenesis refers to the growth of new blood vessels that may help those suffering from coronary heart disease by increasing blood flow associated with the disease. The article, titled “Tomorrow’s Drugs,” can be viewed at www.cvbt.com.
The Pharmaceutical Executive article profiles new technologies that have made it possible to treat disease in unprecedented ways and highlights CVBT’s development of protein-based angiogenesis as part of a group of therapies that “form a vision for the next generation of drugs.” The feature further states that this next generation of drugs “will transform the industry and the face of healthcare in the decades to come.”
“We are thrilled to be recognized by Pharmaceutical Executive magazine for our work in the field of angiogenesis therapy,” said Dan Montano, CEO, CVBT. “Recognition of our therapy and technology as a potential breakthrough treatment for cardiovascular disease in this article and in BusinessWeek Online’s recent article titled 'The Search for Angiogenesis,' is truly an honor and highlights the need for next-generation therapies. We look forward to bringing to market a viable treatment that will help heart disease patients return to the quality of life they once knew.”
CVBT will begin its Phase II clinical trial of its drug candidate, CVBT-141H, in September/October of this year in patients with severe coronary heart disease.
About CardioVascular BioTherapeutics
CVBT is a biopharmaceutical company developing drug candidates formulated with human Fibroblast Growth Factor-1 (FGF-1) to treat a number of diseases characterized by inadequate blood flow to a tissue or organ. The Phase II trial to treat severe coronary heart disease has been approved by the FDA and dosing is planned to begin in the fall of this year. Additionally, CVBT is close to completion of a Phase I clinical trial for dermal diabetic and venous ulcer healing, where its drug candidate CVBT-141B was applied topically. CVBT also has initiated a Phase I clinical trial using a third drug candidate, CVBT-141C, in patients with Peripheral Arterial Disease.
This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of CVBT drug candidates, market acceptance of CVBT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage and financial performance. For a more detailed discussion of these and associated risks, see the company's most recent documents filed with the Securities and Exchange Commission.
Schwartz Communications
Nicki Polatin, 415-512-0770
Erin Walsh, 781-684-0770
cvbt@schwartz-pr.com